Leflunomide-treated tumors that inhibit a key enzyme for ab initio synthesis of pyrimidine exhibited reduced CTLA-4+ T cells, suggesting reduced intra-tumor T cell depletion and possibly increased anti-tumor immunity. The gene discussed is CTLA4; the disease is neoplasm.